<SEC-DOCUMENT>0001193125-20-190075.txt : 20200812
<SEC-HEADER>0001193125-20-190075.hdr.sgml : 20200812
<ACCEPTANCE-DATETIME>20200709072401
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-20-190075
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Relay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001812364
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-370-8837

	MAIL ADDRESS:	
		STREET 1:		399 BINNEY STREET
		STREET 2:		2ND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g924757dsp01aaa.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD ROWSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Goodwin Procter <SMALL>LLP&nbsp;</SMALL> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">100 Northern Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Boston, MA
02210&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">goodwinlaw.com
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 570 1000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;9, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jeffrey
Gabor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christine Westbrook </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rolf Sundwall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terence O&#146;Brien </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Healthcare and Insurance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relay Therapeutics, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Filed June&nbsp;24, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;333-239412</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of our client,
Relay Therapeutics,&nbsp;Inc. (the &#147;<B>Company</B>&#148;), we are responding to the comments from the Staff (the &#147;<B>Staff</B>&#148;) of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) relating to the
Company&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (the &#147;<B>Registration Statement</B>&#148;) contained in the Staff&#146;s letter dated July&nbsp;8, 2020 (the &#147;<B>Comment
Letter</B>&#148;).&nbsp;In response to the comments set forth in the Comment Letter, the Company has revised the Registration Statement and is filing an Amendment No.&nbsp;1 to the Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Amended Registration Statement</B>&#148;) together with this response letter.&nbsp;The Amended Registration Statement also contains certain additional updates and revisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are the Company&#146;s responses to the Staff&#146;s comments in the Comment Letter.&nbsp;The responses and information below
are based on information provided to us by the Company.&nbsp;For convenience, the Staff&#146;s comments are repeated below in italics, followed by the Company&#146;s response to the comments as well as a summary of the responsive actions
taken.&nbsp;We have included page&nbsp;numbers to refer to the location in the Amended Registration Statement submitted herewith where the revised language addressing a particular comment appears.&nbsp;Capitalized terms used but not defined herein
are used herein as defined in the Amended Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g924757dsp01aaa.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed June&nbsp;24, 2020
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our solution, <FONT
STYLE="white-space:nowrap">RLY-1971,</FONT> page 105 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to comment 15 and do not agree with your conclusion that these comparisons are
appropriate without additional disclosure that provides appropriate context for investors, e.g., as a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> list, discussion that highlights the early stage nature of your <FONT
STYLE="white-space:nowrap">RLY-4008</FONT> program, differing dosages and patient populations and, as referenced in your response, that you will need to generate the bulk of the clinical data necessary to support marketing approval.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>RESPONSE: </B>The Company respectfully advises the Staff that it has made revisions on pages 96, 114, and 116 of
the Amended Registration Statement to remove any references to these comparisons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Our clinical development plan, page 112 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to comment 14 and your disclosure on page 3 that you are evaluating the safety and
tolerability of <FONT STYLE="white-space:nowrap">RLY-1971</FONT> in a Phase 1 dose escalation study. Please expand your disclosure to state the current size of the clinical trial population. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>RESPONSE: </B>The Company respectfully advises the Staff that it has added disclosure on pages 3, 94 and 113 of the Amended Registration
Statement to indicate that the Company has dosed 10 patients as of July&nbsp;8, 2020 and plans to enroll approximately 52 patients in its Phase 1 dose escalation study of <FONT STYLE="white-space:nowrap">RLY-1971.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Collaboration and License Agreement with D. E. Shaw Research, LLC, page 133</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your response to comment 16. Please revise the summary to clearly state that <FONT
STYLE="white-space:nowrap">RLY-1941</FONT> is currently <FONT STYLE="white-space:nowrap">co-owned</FONT> with D. E. Shaw Research and explain your development and commercialization rights. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>RESPONSE: </B>The Company respectfully advises the Staff that it has revised its disclosure on pages 133 and 134 to clearly state that
intellectual property rights covering the composition of matter for <FONT STYLE="white-space:nowrap">RLY-1971</FONT> are currently <FONT STYLE="white-space:nowrap">co-owned</FONT> with D. E. Shaw Research and add further explanation regarding the
Company&#146;s development and commercialization rights. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gabriela Morales-Rivera</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gabriela Morales-Rivera</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sanjiv K. Patel, <I>Relay Therapeutics, Inc. </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brian Adams, <I>Relay Therapeutics, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mitchell S. Bloom, <I>Goodwin Procter LLP </I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">William D. Collins, <I>Goodwin Procter LLP </I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g924757dsp01aaa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g924757dsp01aaa.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M5G=GJ-NYDMXW/5E!KTHNZN?.27+)I$M424=6U6UT339K^\D"01#)/<^@'O2
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M-Y)%96'!&>E 'F'CKPI-X6U9DAW'3;EM\)[ C^$^XS^1H ]?^&'_ "3K2O\
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M2)%1!T"C %=JBH['F-N3NR0#%4(6@ H * "@ H * "@ H * "@ H * "@ H
4* "@ H * "@ H * "@!1TIB/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
